Cerus Corporation

CERS Healthcare Medical Devices

In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.

2.20 0.06 −2.65%
Market cap
$455.5M
P/E
0.0×
Fwd P/E
−81.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(27.41%) (25.65%) (15.34%) (10.69%)
Piotroski F-Score
5 5 5 5
ROA
(7.89%) (7.39%) (4.45%) (3.24%)
ROIC
(8.65%) (8.22%) (2.74%) (1.27%)
Return on Tangible Assets
(18.72%) (18.88%) (12.37%) (8.38%)
Average Days of Receivables
48.09 47.42 43.71 45.59
Free Cash Flow per Share
0.00 0.01 (0.01) (0.01)
Free Cash Flow
0.17 1.11 (1.22) (1.83)
Capital Expenditures
(3.40) (3.73) (3.85) (4.25)
Other line items
Cash ROIC
0.07% 0.48% (0.52%) (0.95%)
Accounts Receivable Turnover
8.35 7.77 8.80 7.95
Accounts Payable Turnover
4.32 3.78 3.42 3.32
Inventory Turnover
1.99 1.99 1.86 1.77
Average Days of Payables
104.14 108.93 113.98 115.16
Days of Inventory on Hand
217.28 218.20 219.16 226.12
Tax Rate
0.02 0.02 0.04 0.06
Research and Development Expense of Revenue
29.55% 28.97% 26.81% 24.65%
Selling, General and Administrative Expense of Revenue
35.15% 34.61% 32.91% 33.17%
Share Based Compensation of Revenue
10.37% 9.78% 8.63% 8.45%
Interest Coverage
(1.13) (1.04) (0.39) (0.21)
Operating CF/Net income
(0.22) (0.31) (0.28) (0.36)
Depreciation/Fixed assets
0.21 0.15 0.17 0.18
Capex/Depreciation
(2.49) (2.61) (2.46) (2.52)
Revenue per Share
1.18 1.23 1.26 1.24
Operating CF per Share
0.02 0.03 0.01 0.01
Capex per Share
(0.02) (0.02) (0.02) (0.02)
Capex to Sales
0.02 0.02 0.02 0.02

Fold the line items

Columns are period end dates